Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

149
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
149
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

298
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
298
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

477
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
477
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

560
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
560
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disseminated <i>Mycobacterium haemophilum</i> Infection Complicating Immunosuppressive Therapy in HLA-A29 Positive Birdshot Chorioretinopathy: Case Report.

Case reports in ophthalmology·2026
Same author

Blue Dacryorrhea After Inadvertent Infiltration of the Lacrimal Gland During Scleral Tattooing.

Cornea·2026
Same author

Comparative Outcomes of Exogenous and Endogenous MRSA Vs MSSA Endophthalmitis.

Ocular immunology and inflammation·2026
Same author

Artificial intelligence for detection and staging of Alzheimer's disease using retinal images.

The Cochrane database of systematic reviews·2026
Same author

Imaging Biomarkers To Predict Progression of Intermediate AMD with Avascular Pigment Epithelial Detachment in the University of Colorado AMD Registry.

Research square·2026
Same author

Menopausal Hormone Therapy and Conversion from Intermediate to Advanced Age-Related Macular Degeneration.

Journal of vitreoretinal diseases·2026

Related Experiment Video

Updated: Jul 17, 2025

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

1.5K

Corticosteroid implants for chronic non-infectious uveitis.

Amit Reddy1, Su-Hsun Liu1,2, Christopher J Brady3,4

  • 1Department of Ophthalmology, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, Colorado, USA.

The Cochrane Database of Systematic Reviews
|August 29, 2023
PubMed
Summary
This summary is machine-generated.

Corticosteroid implants may reduce uveitis recurrence but increase risks of cataracts and elevated intraocular pressure (IOP). Further research is needed to clarify their long-term efficacy and safety in treating non-infectious uveitis.

More Related Videos

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

224
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.3K

Related Experiment Videos

Last Updated: Jul 17, 2025

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

1.5K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

224
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.3K

Area of Science:

  • Ophthalmology
  • Inflammatory Diseases
  • Pharmacology

Background:

  • Uveitis, a group of intraocular inflammatory diseases, is a leading cause of vision loss, particularly in the working-age population.
  • Corticosteroids are the primary treatment for non-infectious uveitis, administered via various routes including intravitreal implants.

Purpose of the Study:

  • To evaluate the efficacy and safety of intravitreal steroid implants for chronic non-infectious posterior, intermediate, and panuveitis.

Main Methods:

  • A systematic review of randomized controlled trials comparing fluocinolone acetonide (FA) or dexamethasone (DEX) intravitreal implants against standard care or sham procedures.
  • Included studies involved participants of all ages with chronic non-infectious uveitis and vision better than hand-motion, with follow-up of at least six months.

Main Results:

  • Corticosteroid implants may reduce uveitis recurrence by approximately 60% compared to sham procedures (low-certainty evidence) and improve best-corrected visual acuity (BCVA) at six months.
  • Compared to standard care, implants may reduce recurrence by 54% at 24 months but show little to no improvement in BCVA.
  • Implants may increase the risk of cataract formation and elevated intraocular pressure (IOP), necessitating interventions, but do not increase risks of endophthalmitis, retinal tear, or detachment.

Conclusions:

  • Confidence is limited regarding the superiority of corticosteroid implants over sham or standard care for reducing uveitis recurrence.
  • While implants may offer benefits, they are associated with increased risks of cataract progression and elevated IOP, requiring monitoring and management.
  • Further trials with standardized outcomes and varying doses/durations are needed to fully elucidate the efficacy and safety profiles of these steroid implants.